Skip to main navigation Skip to search Skip to main content

Growth and nutritional status, and their association with lung function: A study from the international Primary Ciliary Dyskinesia Cohort

  • on behalf of the PCD Israeli Consortium, Laura Behan
  • , on behalf of the Swiss PCD Group, Annick Clement
  • , on behalf of the French Reference Centre for Rare Lung Diseases, Suzanne Crowley

Research output: Contribution to journalArticlepeer-review

48 Scopus citations

Abstract

Chronic respiratory disease can affect growth and nutrition, which can influence lung function. We investigated height, body mass index (BMI), and lung function in patients with primary ciliary dyskinesia (PCD). In this study, based on the international PCD (iPCD) Cohort, we calculated z-scores for height and BMI using World Health Organization (WHO) and national growth references, and assessed associations with age, sex, country, diagnostic certainty, age at diagnosis, organ laterality and lung function in multilevel regression models that accounted for repeated measurements. We analysed 6402 measurements from 1609 iPCD Cohort patients. Height was reduced compared to WHO (z-score −0.12, 95% CI −0.17 to −0.06) and national references (z-score −0.27, 95% CI −0.33 to −0.21) in male and female patients in all age groups, with variation between countries. Height and BMI were higher in patients diagnosed earlier in life (p=0.026 and p<0.001, respectively) and closely associated with forced expiratory volume in 1 s and forced vital capacity z-scores (p<0.001). Our study indicates that both growth and nutrition are affected adversely in PCD patients from early life and are both strongly associated with lung function. If supported by longitudinal studies, these findings suggest that early diagnosis with multidisciplinary management and nutritional advice could improve growth and delay disease progression and lung function impairment in PCD.

Original languageEnglish
Article number1701659
JournalEuropean Respiratory Journal
Volume50
Issue number6
DOIs
StatePublished - 1 Dec 2017

Bibliographical note

Publisher Copyright:
Copyright © ERS 2017

Funding

Support statement: The development of the international Primary Ciliary Dyskinesia (iPCD) Cohort is funded by the European Union’s Seventh Framework Programme (EG-GA No.35404 BESTCILIA: Better Experimental Screening and Treatment for Primary Ciliary Dyskinesia). The primary ciliary dyskinesia (PCD) research at the Institute of Social and Preventive Medicine (ISPM) in Bern is supported by the Swiss National Science Foundation (SNF 320030_173044) and receives national funding from the Lung Leagues of Bern, St. Gallen, Vaud, Ticino and Valais, as well as the Milena-Carvajal Pro Kartagener Foundation. C. Kuehni is supported by the Swiss National Science Foundation (SNF32003B_162820 and SNF32003B_144068) while the national PCD service in Southampton and London is funded by the National Health Service (NHS) in England. The researchers participate in the Better Evidence to Advance Therapeutic Options for PCD (BEAT-PCD) network (COST action BM 1407). A Swiss National Science Foundation fellowship (PZ00P3_147987) supports B.D. Spycher. Swiss Cancer Research grants (KLS-3412-02-2014 and KLS-3644-02-2015) support F. Belle. The AAIR Charity (Reg. No. 1129698) supports L. Behan. S. Dell, T. Ferkol, M. Knowles, M.W. Leigh and S.D. Sagel are supported by the National Institutes of Health (U54HL096458). S.D. Sagel is also supported by local funding (CTSA NIH/NCATS Colorado UL1TR000154). Funding information for this article has been deposited with the Crossref Funder Registry. The development of the international Primary Ciliary Dyskinesia (iPCD) Cohort is funded by the European Union's Seventh Framework Programme (EG-GA No.35404 BESTCILIA: Better Experimental Screening and Treatment for Primary Ciliary Dyskinesia). The primary ciliary dyskinesia (PCD) research at the Institute of Social and Preventive Medicine (ISPM) in Bern is supported by the Swiss National Science Foundation (SNF 320030_173044) and receives national funding from the Lung Leagues of Bern, St. Gallen, Vaud, Ticino and Valais, as well as the Milena-Carvajal Pro Kartagener Foundation. C. Kuehni is supported by the Swiss National Science Foundation (SNF32003B_162820 and SNF32003B_144068) while the national PCD service in Southampton and London is funded by the National Health Service (NHS) in England. The researchers participate in the Better Evidence to Advance Therapeutic Options for PCD (BEAT-PCD) network (COST action BM 1407). A Swiss National Science Foundation fellowship (PZ00P3_147987) supports B.D. Spycher. Swiss Cancer Research grants (KLS-3412-02-2014 and KLS-3644-02-2015) support F. Belle. The AAIR Charity (Reg. No. 1129698) supports L. Behan. S. Dell, T. Ferkol, M. Knowles, M.W. Leigh and S.D. Sagel are supported by the National Institutes of Health (U54HL096458). S.D. Sagel is also supported by local funding (CTSA NIH/NCATS Colorado UL1TR000154). Funding information for this article has been deposited with the Crossref Funder Registry. We want to thank all patients in the PCD cohort and their families, and we are grateful to the PCD patient organisations that closely collaborated with us. We thank all the researchers in the participating centres who helped collect and enter data, and worked closely with us throughout building the iPCD Cohort. We thank Zorica Zivkovic (Children's Hospital for Lung Diseases and TB, Medical Centre ?Dr Dragisa Misovic?, Belgrade, Serbia) for contributing patients from her centre. We appreciate the work of Edwige Collaud and Anna Bettina Meier (Institute of Social and Preventive Medicine, University of Bern, Switzerland) who helped us with the height and BMI z-score calculations for some countries. We also thank Kali Tal and Christopher Ritter (Institute of Social and Preventive Medicine, University of Bern, Switzerland) for their editorial suggestions.

FundersFunder number
Children's Hospital for Lung Diseases
Milena-Carvajal Pro Kartagener FoundationSNF32003B_162820, SNF32003B_144068
National Health Service
National Institutes of HealthUL1TR000154
National Heart, Lung, and Blood InstituteU54HL096458
Seventh Framework Programme35404
European Cooperation in Science and TechnologyPZ00P3_147987
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung320030_173044
Seventh Framework Programme
Swiss Cancer Research Foundation1129698, KLS-3412-02-2014, KLS-3644-02-2015

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Fingerprint

    Dive into the research topics of 'Growth and nutritional status, and their association with lung function: A study from the international Primary Ciliary Dyskinesia Cohort'. Together they form a unique fingerprint.

    Cite this